Aethlon Medical - While maintaining rigid cost controls generally (OpEx declined 26% y/y in FY 25)
While maintaining rigid cost controls generally (OpEx declined 26% y/y in FY 25), AEMD continues pre-clinical research and analysis of the...
221 Views
Long COVID is estimated to lead to about $2b-$6.5b of related costs/year for the ~44 to 48m people suffering in the U.S.
Long COVID is estimated to lead to about $2b-$6.5b of related costs/year for the ~44 to 48m people suffering in the U.S. but no treatment has...
479 Views
Aethlon Medical Inc - The company expects to conduct a capital raise that
The company expects to conduct a capital raise that, along with the expected (and recent) exercise of outstanding warrants, could extend its cash...
219 Views
AEMD Treats First Patient in Australian Safety
Zacks Small-Cap Research Note for Aethlon Medical (AEMD)
307 Views
AEMD recently made some headcount reductions and other cost reductions and stands to benefit from the up to 43.5% cash tax rebate on clinical trial-related R&D costs in Australia.
AEMD recently made some headcount reductions and other cost reductions and stands to benefit from the up to 43.5% cash tax rebate on clinical...
178 Views